Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis
Author:
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Link
https://www.nature.com/articles/s41409-022-01650-5.pdf
Reference25 articles.
1. Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97:1916–24. https://doi.org/10.3324/haematol.2012.066100.
2. Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: a review. Br J Haematol. 2011;152:524–42.
3. Estey E, de Lima M, Tibes R, Pierce S, Kantarjian H, Champlin R, et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2007;109:1395–1400. https://doi.org/10.1182/blood-2006-05-021907.
4. Flannelly C, Tan BEX, Tan JL, McHugh CM, Sanapala C, Lagu T, et al. Barriers to hematopoietic cell transplantation for adults in the united states: a systematic review with a focus on age. Biol Blood Marrow Transplant. Published online 20 Sept 2020. https://doi.org/10.1016/j.bbmt.2020.09.013.
5. Bhatt VR, Chen B, Lee SJ. Use of hematopoietic cell transplantation in younger patients with acute myeloid leukemia: a national cancer database study. Bone Marrow Transpl. 2018;53:873–9. https://doi.org/10.1038/s41409-018-0105-9.
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Outcomes of older adults undergoing allogeneic hematopoietic cell transplantation with post‐transplant cyclophosphamide based prophylaxis;European Journal of Haematology;2024-08-14
2. Zelluläre Therapien im Alter: Everything, everywhere, all at once?;InFo Hämatologie + Onkologie;2024-07
3. Cellular therapies in older adults with hematological malignancies: A case-based, state-of-the-art review;Journal of Geriatric Oncology;2024-04
4. Transplantation and Cellular Therapy for Older Adults—The MSK Approach;Current Hematologic Malignancy Reports;2024-02-09
5. Development and Validation of a Concise Objectifiable Risk Evaluation Score for Non-Relapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation;Cancers;2024-01-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3